Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités

View original at globenewswire.com
“Trésorerie et équivalents de trésorerie de 194 millions de dollars au 31 décembre 2025”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DBV is pleased with the progress made in strengthening capabilities and building a company ready for the launch of Viaskin Peanut

    60% confidence

  • These estimates are based on the Company's current forecasts and exclude any additional expenses related to programs other than Viaskin Peanut, or resulting from potential licensing or acquisition operations of additional product candidates or technologies

    60% confidence

  • The Company may have based these estimates on assumptions that could prove to be inaccurate, and could consequently use its resources more quickly than anticipated

    60% confidence

  • Management estimates that the Company has sufficient resources to fund operations through the second quarter of 2027

    60% confidence

  • DBV remains firmly committed to making Viaskin Peanut available to children aged 1 to 7 years allergic to peanuts

    60% confidence

  • We approached 2025 focused on strengthening the company's financial position, completing the VITESSE study, launching the COMFORT Toddlers study, and preparing for the BLA submission and potential commercial launch in the United States

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com